Related scientific articles (all)

Targeting RANKL in breast cancer: bone metastasis and beyond.

Authors : Azim H, Azim HA
Year : 2013
Journal : Expert Rev Anticancer Ther
Volume : 13(2)
Pages : 195-201

Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.

Authors : Saghatchian M, Mook S, Pruneri G, Viale G, Glas AM, Guerin S, Cardoso F, Piccart-Gebhart M, Tursz T, Delaloge S, van t Veer L
Year : 2013
Journal : Breast
Volume : 22(5)
Pages : 682-90

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.

Authors : Azim HA, Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M, Neven P, Symmans WF, Thompson A, André F, Loi S, Swanton C
Year : 2013
Journal : Ann Oncol
Volume : 24(3)
Pages : 647-54

Multigene assays for late recurrence of breast cancer.

Authors : Ignatiadis M
Year : 2013
Journal : Lancet Oncol
Volume : 14(11)
Pages : 1029-30

Breast cancer in young women - Special Issue.

Authors : Azim HA, Peccatori FA
Year : 2013
Journal : J Thorac Dis
Volume : 5(Suppl 1)
Pages : S1

Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.

Authors : Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart-Gebhart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI
Year : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(9)
Pages : 654-63

Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding?

Authors : Pistilli B, Bellettini G, Giovannetti E, Codacci-Pisanelli G, Azim HA, Benedetti G, Sarno MA, Peccatori FA
Year : 2013
Journal : Cancer Treat Rev
Volume : 39(3)
Pages : 207-11

Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting.

Authors : Peeters DJ, De Laere B, Van den Eynden GG, Van Laere SJ, Rothé F, Ignatiadis M, Sieuwerts AM, Lambrechts D, Rutten A, van Dam PA, Pauwels P, Peeters M, Vermeulen PB, Dirix LY
Year : 2013
Journal : Br J Cancer
Volume : 108(6)
Pages : 1358-67

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.

Authors : Zabaglo L, Stoss O, Rüschoff J, Zielinski D, Salter J, Arfi M, Bradbury I, Dafni U, Piccart-Gebhart M, Procter M, Dowsett M
Year : 2013
Journal : Ann Oncol
Volume : 24(11)
Pages : 2761-6

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

Authors : Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, de Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell orto P, Larsimont D, Steinberg I, Gelber Rd, Piccart-Gebhart M, Viale G, Di Leo A
Year : 2013
Journal : Ann Oncol
Volume : 24(5)
Pages : 1203-11

Pancreatic Tuberculosis Diagnosed by EUS: One Disease, Many Faces.

Authors : Vafa H, Arvanitakis M, Matos C, Demetter P, Eisendrath P, Toussaint E, Hittelet AB, Deviere J, Delhaye M
Year : 2013
Journal : JOP
Volume : 14(3)
Pages : 256-60

Autoimmune haemolytic anaemia in a patient treated with capecitabine.

Authors : Sideris S, Loizidou A, Georgala A, Lebrun F, Gil T, Awada A, Piccart-Gebhart M, Cardoso F
Year : 2013
Journal : Acta Clin Belg
Volume : 68(2)
Pages : 135-7

Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience.

Authors : Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu B, Baselga J, Perez EA, Piccart-Gebhart M
Year : 2013
Journal : Oncologist
Volume : 18(2)
Pages : 134-40

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.

Authors : Burris HA, Lebrun F, Rugo HS, Beck JT, Piccart-Gebhart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S
Year : 2013
Journal : Cancer
Volume : 119(10)
Pages : 1908-15

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.

Authors : Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : PLoS One
Volume : 8(8)
Pages : e66848

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98.

Authors : Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(7)
Pages : 860-7

The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.

Authors : Klastersky J, Paesmans M
Year : 2013
Journal : Support Care Cancer
Volume : 21(5)
Pages : 1487-95

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Authors : Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO
Year : 2013
Journal : Eur. J. Cancer
Volume : 49(15)
Pages : 3219-28

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24
Pages : 377-384

How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.

Authors : Pinto AC, de Azambuja E, Piccart-Gebhart M
Year : 2013
Journal : Breast Care (Basel)
Volume : 8(4)
Pages : 264-269